Hypertension Management

First-Line Treatment

• The American Heart Association recommends using first-line antihypertensive agents alone or in combination, with labetalol as a reasonable alternative for patients experiencing side effects, or in combination with nifedipine for uncontrolled blood pressure 1
• The European Society of Cardiology guidelines recommend labetalol or nicardipine and magnesium sulphate as first-line treatment for severe hypertension in pregnancy 2

Hypertensive Emergencies

• The European Society of Cardiology recommends labetalol as first-line treatment for malignant hypertension, with nicardipine as an alternative, and immediate treatment with labetalol for hypertensive encephalopathy 2
• The American Heart Association recommends a target heart rate of ≤60 beats per minute and a target systolic blood pressure of <120 mmHg for patients with acute aortic syndromes or hypertensive emergencies 3, 4, 5
• The American Heart Association and the European Society of Cardiology recommend aiming for a gradual reduction of 10-15% in the first hour, rather than rapid normalization, and a 10-15% reduction in mean arterial pressure initially 2, 6, 2

Combination Therapy

• The American Heart Association recommends starting with one agent, typically nifedipine, and adding a second agent if blood pressure remains uncontrolled, considering the use of a thiazide or thiazide-like diuretic as the first option 7, 8
• The American Heart Association recommends using a loop diuretic instead of thiazides for patients with a glomerular filtration rate (GFR) <30 mL/min 7
• The American Heart Association recommends considering an inhibitor of the renin-angiotensin system (ACE inhibitor or ARB) as a second option, and notes that the combination of amlodipine, labetalol, and telmisartan has different mechanisms of action 8, 9
• The American Heart Association suggests considering nitroprusside sodium or increasing the infusion of labetalol up to 3 mg/kg/h or adding nicardipine (5 mg/h IV) in cases of emergency hypertension 10

Labetalol Administration and Monitoring

• Labetalol is contraindicated in patients with reactive airway disease, COPD, second or third degree heart block, bradycardia, or decompensated heart failure, and elderly patients may require lower doses and should be used with caution 10, 4
• The American Heart Association recommends an initial dose of 0.3-1.0 mg/kg (maximum 20 mg) slow IV injection, with repeat doses every 10 minutes as needed, and a maximum cumulative dose of 300 mg 10, 4
• A continuous infusion of labetalol can be administered at a rate of 0.4-1.0 mg/kg/h up to 3 mg/kg/h, with a maximum cumulative dose consideration, as shown in the following table:

2, 11, 10, 4

• Blood pressure should be monitored every 15 minutes for the first 2 hours after administration, then every 30 minutes for 6 hours, and then hourly, with common adverse effects including postural hypotension, dizziness, gastrointestinal disturbances, fatigue, and headache 12, 4, 6, 4
• The American Heart Association recommends monitoring for postural hypotension, especially 2-4 hours after dosing, and continuous blood pressure monitoring is essential, preferably with arterial line for hypertensive emergencies 4

Special Considerations

• Labetalol is particularly valuable in patients with adrenergic crises from pheochromocytoma, with IV dosing of 1-2 mg/kg twice weekly as bolus followed by continuous infusion, according to the European Society of Cardiology, and is effective and well-tolerated in pregnant women with hypertension 13, 14
• The transition to oral therapy can occur after 24 hours if hemodynamic goals have been achieved, with an initial oral dose of 200 mg, and a long-term hypertension management plan should be developed based on patient characteristics, with a strength of evidence supporting this approach 5, 15, 2